Share Price and Basic Stock Data
Last Updated: January 14, 2026, 10:14 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Vaishali Pharma Ltd operates in the pharmaceuticals sector, reporting a market capitalization of ₹109 Cr and a share price of ₹8.32. The company has experienced fluctuating sales, with the latest quarterly sales for September 2023 recorded at ₹12.57 Cr, a decline from ₹13.42 Cr in June 2023. However, the company demonstrated resilience with a notable increase in sales of ₹27.90 Cr for December 2023, reflecting a recovery trend. Yearly sales figures showed a decrease from ₹76 Cr in March 2022 to ₹70 Cr in March 2023, but projections for March 2025 stand at ₹99 Cr, indicating a potential upward trajectory. This trend highlights the company’s ability to navigate market challenges and capitalize on growth opportunities. Overall, the sales performance suggests a significant potential for recovery and growth in future quarters, although recent quarterly fluctuations indicate volatility that stakeholders should monitor closely.
Profitability and Efficiency Metrics
Vaishali Pharma’s profitability metrics indicate a challenging operational environment, with an operating profit margin (OPM) standing at 4.16%. The quarterly OPM has shown significant volatility, peaking at 21.08% in September 2023 but falling to just 4.16% in the latest quarter. The company reported a net profit of ₹0.44 Cr in March 2023, which declined sharply to a loss of ₹4.68 Cr in March 2024, followed by a slight recovery to ₹1.28 Cr by June 2025. The return on equity (ROE) is notably low at 1.52%, and the return on capital employed (ROCE) stands at 4.93%, both reflecting inefficiencies compared to industry norms. The cash conversion cycle (CCC) of 77 days indicates a relatively slow turnover of inventory and receivables, which may hinder profitability. The company needs to enhance operational efficiencies to improve its profitability metrics and overall financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Vaishali Pharma reveals a moderate financial structure, with total borrowings reported at ₹16 Cr and reserves amounting to ₹41 Cr. The current ratio is a healthy 2.61, indicating sufficient liquidity to meet short-term obligations. However, the interest coverage ratio (ICR) of 2.08x suggests that the company can cover its interest expenses, but only comfortably, which raises concerns about financial stability. The price-to-book value (P/BV) ratio stands at 2.53x, higher than typical sector ranges, indicating that the stock may be overvalued relative to its book value. Furthermore, the total debt to equity ratio is a manageable 0.17, reflecting a conservative approach to leverage. Despite these strengths, the overall financial ratios suggest that the company must focus on improving profitability and operational efficiency to strengthen its balance sheet further.
Shareholding Pattern and Investor Confidence
Vaishali Pharma’s shareholding pattern shows a diversified ownership structure, with promoters holding 26.32% of the company, while the public holds a substantial 73.68%. The lack of foreign institutional investment (FIIs) indicates a potential lack of confidence from international investors, which may limit the company’s growth prospects. The number of shareholders has increased significantly from 8,954 in December 2022 to 27,752 by September 2025, highlighting growing public interest in the company. However, the absence of domestic institutional investors (DIIs) raises questions about institutional confidence in the stock. This increasing number of shareholders may provide some stability, but the reliance on public investment without institutional backing poses risks, particularly during market downturns. The company’s financial performance and strategic initiatives will be crucial in maintaining investor confidence moving forward.
Outlook, Risks, and Final Insight
Looking ahead, Vaishali Pharma faces both opportunities and challenges. The potential for revenue growth is significant, especially if the company can stabilize its sales and improve profitability metrics. However, the volatility in quarterly earnings and the low ROE present considerable risks that management must address. Additionally, the reliance on public investors without substantial institutional support could hinder strategic growth initiatives. The company’s ability to enhance operational efficiency, reduce the cash conversion cycle, and attract institutional investment will be critical in shaping its future. In a favorable economic environment, the company could leverage its increasing shareholder base to drive growth, while adverse market conditions could exacerbate its existing financial challenges. The management’s strategic focus on operational improvements and market positioning will ultimately determine the company’s trajectory in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 89.9 Cr. | 23.4 | 784/22.8 | 0.88 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 2,686 Cr. | 167 | 212/124 | 118 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 43.8 Cr. | 3.43 | 8.19/3.30 | 4.93 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,355.82 Cr | 209.12 | 325.03 | 219.28 | 0.26% | 11.73% | 22.92% | 9.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.16 | 20.09 | 26.24 | 13.42 | 12.57 | 27.90 | 32.40 | 18.08 | 20.79 | 27.91 | 32.25 | 23.75 | 33.45 |
| Expenses | 10.57 | 16.53 | 25.46 | 11.11 | 9.92 | 24.95 | 39.19 | 15.73 | 18.37 | 26.55 | 38.29 | 22.38 | 32.06 |
| Operating Profit | 2.59 | 3.56 | 0.78 | 2.31 | 2.65 | 2.95 | -6.79 | 2.35 | 2.42 | 1.36 | -6.04 | 1.37 | 1.39 |
| OPM % | 19.68% | 17.72% | 2.97% | 17.21% | 21.08% | 10.57% | -20.96% | 13.00% | 11.64% | 4.87% | -18.73% | 5.77% | 4.16% |
| Other Income | 0.74 | 0.53 | 0.53 | 0.36 | 0.30 | 0.47 | 0.91 | 0.42 | 0.71 | 1.07 | 1.00 | 0.84 | 0.84 |
| Interest | 0.53 | 0.42 | 0.54 | 0.43 | 0.47 | 0.43 | 0.40 | 0.38 | 0.38 | 0.38 | 0.44 | 0.33 | 0.40 |
| Depreciation | 0.14 | 0.12 | 0.15 | 0.12 | 0.12 | 0.12 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.14 | 0.17 |
| Profit before tax | 2.66 | 3.55 | 0.62 | 2.12 | 2.36 | 2.87 | -6.42 | 2.27 | 2.63 | 1.93 | -5.60 | 1.74 | 1.66 |
| Tax % | 24.81% | 25.07% | 29.03% | 25.00% | 27.97% | 26.13% | -26.95% | 25.11% | 25.10% | 24.87% | -23.39% | 26.44% | 28.31% |
| Net Profit | 1.99 | 2.66 | 0.44 | 1.59 | 1.70 | 2.11 | -4.68 | 1.70 | 1.97 | 1.44 | -4.29 | 1.28 | 1.18 |
| EPS in Rs | 0.19 | 0.25 | 0.04 | 0.15 | 0.16 | 0.20 | -0.44 | 0.16 | 0.18 | 0.13 | -0.40 | 0.12 | 0.09 |
Last Updated: December 28, 2025, 3:31 pm
Below is a detailed analysis of the quarterly data for Vaishali Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 33.45 Cr.. The value appears strong and on an upward trend. It has increased from 23.75 Cr. (Jun 2025) to 33.45 Cr., marking an increase of 9.70 Cr..
- For Expenses, as of Sep 2025, the value is 32.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.38 Cr. (Jun 2025) to 32.06 Cr., marking an increase of 9.68 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.37 Cr. (Jun 2025) to 1.39 Cr., marking an increase of 0.02 Cr..
- For OPM %, as of Sep 2025, the value is 4.16%. The value appears to be declining and may need further review. It has decreased from 5.77% (Jun 2025) to 4.16%, marking a decrease of 1.61%.
- For Other Income, as of Sep 2025, the value is 0.84 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.84 Cr..
- For Interest, as of Sep 2025, the value is 0.40 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.33 Cr. (Jun 2025) to 0.40 Cr., marking an increase of 0.07 Cr..
- For Depreciation, as of Sep 2025, the value is 0.17 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.14 Cr. (Jun 2025) to 0.17 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.66 Cr.. The value appears to be declining and may need further review. It has decreased from 1.74 Cr. (Jun 2025) to 1.66 Cr., marking a decrease of 0.08 Cr..
- For Tax %, as of Sep 2025, the value is 28.31%. The value appears to be increasing, which may not be favorable. It has increased from 26.44% (Jun 2025) to 28.31%, marking an increase of 1.87%.
- For Net Profit, as of Sep 2025, the value is 1.18 Cr.. The value appears to be declining and may need further review. It has decreased from 1.28 Cr. (Jun 2025) to 1.18 Cr., marking a decrease of 0.10 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.09. The value appears to be declining and may need further review. It has decreased from 0.12 (Jun 2025) to 0.09, marking a decrease of 0.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:26 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 95 | 67 | 64 | 68 | 75 | 60 | 54 | 76 | 70 | 86 | 99 | 117 |
| Expenses | 118 | 95 | 66 | 60 | 65 | 73 | 59 | 51 | 69 | 60 | 85 | 98 | 119 |
| Operating Profit | 2 | -0 | 1 | 3 | 3 | 2 | 1 | 3 | 7 | 9 | 2 | 1 | -2 |
| OPM % | 2% | -0% | 1% | 5% | 4% | 3% | 2% | 5% | 9% | 13% | 2% | 1% | -2% |
| Other Income | 1 | 4 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Profit before tax | 1 | 0 | -0 | 1 | 1 | 1 | 0 | 1 | 6 | 9 | 1 | 1 | -0 |
| Tax % | 50% | -7% | 300% | 32% | 41% | 37% | 62% | 26% | 30% | 25% | 23% | 34% | |
| Net Profit | 0 | 0 | -0 | 1 | 1 | 1 | 0 | 1 | 4 | 7 | 1 | 1 | -0 |
| EPS in Rs | 0.38 | 0.20 | -0.04 | 0.15 | 0.08 | 0.07 | 0.00 | 0.10 | 0.38 | 0.63 | 0.07 | 0.08 | -0.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | -100.00% | 300.00% | 75.00% | -85.71% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | -100.00% | 400.00% | -225.00% | -160.71% | 85.71% |
Vaishali Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 94% |
| 3 Years: | -41% |
| TTM: | -52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 8% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: December 10, 2025, 3:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.50 | 0.50 | 0.50 | 3 | 7 | 7 | 11 | 11 | 11 | 11 | 11 | 26 | 26 |
| Reserves | 3 | 3 | 3 | 1 | 14 | 15 | 11 | 12 | 16 | 30 | 32 | 39 | 41 |
| Borrowings | 19 | 25 | 21 | 23 | 18 | 17 | 17 | 18 | 21 | 15 | 13 | 12 | 16 |
| Other Liabilities | 32 | 17 | 25 | 18 | 25 | 30 | 28 | 46 | 34 | 24 | 24 | 33 | 39 |
| Total Liabilities | 53 | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 82 | 79 | 80 | 110 | 122 |
| Fixed Assets | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Other Assets | 53 | 44 | 48 | 43 | 62 | 67 | 64 | 84 | 80 | 76 | 77 | 107 | 114 |
| Total Assets | 53 | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 82 | 79 | 80 | 110 | 122 |
Below is a detailed analysis of the balance sheet data for Vaishali Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00 Cr..
- For Reserves, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 2.00 Cr..
- For Borrowings, as of Sep 2025, the value is 16.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 12.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 33.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 6.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 122.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 110.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 12.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 107.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 7.00 Cr..
- For Total Assets, as of Sep 2025, the value is 122.00 Cr.. The value appears strong and on an upward trend. It has increased from 110.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 12.00 Cr..
Notably, the Reserves (41.00 Cr.) exceed the Borrowings (16.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -17.00 | -25.00 | -20.00 | -20.00 | -15.00 | -15.00 | -16.00 | -15.00 | -14.00 | -6.00 | -11.00 | -11.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 116 | 133 | 221 | 214 | 240 | 240 | 286 | 453 | 282 | 281 | 209 | 172 |
| Inventory Days | 26 | 13 | 20 | 7 | 11 | 5 | 6 | 5 | 4 | 20 | 2 | 20 |
| Days Payable | 99 | 66 | 145 | 100 | 136 | 130 | 169 | 321 | 163 | 120 | 95 | 116 |
| Cash Conversion Cycle | 43 | 80 | 96 | 121 | 115 | 115 | 123 | 137 | 122 | 181 | 116 | 77 |
| Working Capital Days | 59 | 98 | 25 | 14 | 97 | 98 | 124 | 146 | 111 | 208 | 169 | 231 |
| ROCE % | 19% | 14% | 13% | 16% | 13% | 10% | 7% | 10% | 19% | 22% | 6% | 5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.06 | 0.68 | 6.26 | 3.82 | 0.99 |
| Diluted EPS (Rs.) | 0.06 | 0.64 | 5.91 | 3.82 | 0.99 |
| Cash EPS (Rs.) | 0.09 | 1.14 | 6.74 | 4.25 | 1.40 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 4.98 | 33.41 | 31.26 | 24.99 | 21.26 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 4.98 | 33.41 | 31.26 | 24.99 | 21.26 |
| Revenue From Operations / Share (Rs.) | 7.59 | 80.49 | 66.05 | 71.89 | 50.99 |
| PBDIT / Share (Rs.) | 0.25 | 2.96 | 10.77 | 8.20 | 4.21 |
| PBIT / Share (Rs.) | 0.21 | 2.48 | 10.29 | 7.76 | 3.81 |
| PBT / Share (Rs.) | 0.09 | 0.86 | 8.39 | 5.43 | 1.33 |
| Net Profit / Share (Rs.) | 0.06 | 0.67 | 6.26 | 3.81 | 0.99 |
| PBDIT Margin (%) | 3.32 | 3.67 | 16.30 | 11.39 | 8.26 |
| PBIT Margin (%) | 2.83 | 3.08 | 15.58 | 10.79 | 7.46 |
| PBT Margin (%) | 1.23 | 1.07 | 12.69 | 7.55 | 2.61 |
| Net Profit Margin (%) | 0.82 | 0.83 | 9.47 | 5.30 | 1.94 |
| Return on Networth / Equity (%) | 1.25 | 2.00 | 20.02 | 15.26 | 4.66 |
| Return on Capital Employeed (%) | 4.02 | 5.68 | 23.17 | 27.57 | 14.94 |
| Return On Assets (%) | 0.74 | 0.89 | 8.36 | 4.92 | 1.21 |
| Long Term Debt / Equity (X) | 0.06 | 0.10 | 0.15 | 0.11 | 0.18 |
| Total Debt / Equity (X) | 0.17 | 0.35 | 0.41 | 0.78 | 0.71 |
| Asset Turnover Ratio (%) | 1.04 | 1.09 | 0.86 | 0.90 | 0.70 |
| Current Ratio (X) | 2.61 | 2.25 | 2.27 | 1.47 | 1.37 |
| Quick Ratio (X) | 2.49 | 2.24 | 2.17 | 1.46 | 1.36 |
| Inventory Turnover Ratio (X) | 38.16 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.08 | 1.83 | 5.66 | 3.52 | 1.70 |
| Interest Coverage Ratio (Post Tax) (X) | 1.52 | 1.41 | 4.29 | 2.64 | 1.40 |
| Enterprise Value (Cr.) | 173.94 | 161.15 | 166.55 | 89.17 | 49.85 |
| EV / Net Operating Revenue (X) | 1.76 | 1.87 | 2.39 | 1.18 | 0.92 |
| EV / EBITDA (X) | 52.78 | 50.82 | 14.66 | 10.32 | 11.22 |
| MarketCap / Net Operating Revenue (X) | 1.66 | 1.74 | 2.21 | 0.92 | 0.63 |
| Price / BV (X) | 2.53 | 4.19 | 4.67 | 2.65 | 1.53 |
| Price / Net Operating Revenue (X) | 1.66 | 1.74 | 2.21 | 0.92 | 0.63 |
| EarningsYield | 0.00 | 0.00 | 0.04 | 0.05 | 0.03 |
After reviewing the key financial ratios for Vaishali Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 2.00, marking a decrease of 8.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.68 (Mar 24) to 0.06, marking a decrease of 0.62.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.64 (Mar 24) to 0.06, marking a decrease of 0.58.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 3. It has decreased from 1.14 (Mar 24) to 0.09, marking a decrease of 1.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.59. It has decreased from 80.49 (Mar 24) to 7.59, marking a decrease of 72.90.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 2. It has decreased from 2.96 (Mar 24) to 0.25, marking a decrease of 2.71.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 2.48 (Mar 24) to 0.21, marking a decrease of 2.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has decreased from 0.86 (Mar 24) to 0.09, marking a decrease of 0.77.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 2. It has decreased from 0.67 (Mar 24) to 0.06, marking a decrease of 0.61.
- For PBDIT Margin (%), as of Mar 25, the value is 3.32. This value is below the healthy minimum of 10. It has decreased from 3.67 (Mar 24) to 3.32, marking a decrease of 0.35.
- For PBIT Margin (%), as of Mar 25, the value is 2.83. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 2.83, marking a decrease of 0.25.
- For PBT Margin (%), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 10. It has increased from 1.07 (Mar 24) to 1.23, marking an increase of 0.16.
- For Net Profit Margin (%), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 5. It has decreased from 0.83 (Mar 24) to 0.82, marking a decrease of 0.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 15. It has decreased from 2.00 (Mar 24) to 1.25, marking a decrease of 0.75.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.02. This value is below the healthy minimum of 10. It has decreased from 5.68 (Mar 24) to 4.02, marking a decrease of 1.66.
- For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has decreased from 0.89 (Mar 24) to 0.74, marking a decrease of 0.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.06, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has decreased from 0.35 (Mar 24) to 0.17, marking a decrease of 0.18.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.04. It has decreased from 1.09 (Mar 24) to 1.04, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 2.25 (Mar 24) to 2.61, marking an increase of 0.36.
- For Quick Ratio (X), as of Mar 25, the value is 2.49. This value exceeds the healthy maximum of 2. It has increased from 2.24 (Mar 24) to 2.49, marking an increase of 0.25.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 38.16. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 38.16, marking an increase of 38.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.08. This value is below the healthy minimum of 3. It has increased from 1.83 (Mar 24) to 2.08, marking an increase of 0.25.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has increased from 1.41 (Mar 24) to 1.52, marking an increase of 0.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 173.94. It has increased from 161.15 (Mar 24) to 173.94, marking an increase of 12.79.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 1.87 (Mar 24) to 1.76, marking a decrease of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 52.78. This value exceeds the healthy maximum of 15. It has increased from 50.82 (Mar 24) to 52.78, marking an increase of 1.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
- For Price / BV (X), as of Mar 25, the value is 2.53. This value is within the healthy range. It has decreased from 4.19 (Mar 24) to 2.53, marking a decrease of 1.66.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vaishali Pharma Ltd:
- Net Profit Margin: 0.82%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.02% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.25% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 325.03)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.82%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 706 to 709, 7th Floor, Aravali Business Center, Mumbai Maharashtra 400092 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Atul Arvind Vasani | Chairman & Managing Director |
| Mr. Dewansh Ajay Vasani | Executive Director & CFO |
| Mrs. Jagruti Atul Vasani | Whole Time Director |
| Mr. Manish Bhagwandas Ved | Ind. Non-Executive Director |
| Mr. Pratik Vikram Jakhelia | Ind. Non-Executive Director |
| Mr. Bhaveshkumar Upadhyay | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Vaishali Pharma Ltd?
Vaishali Pharma Ltd's intrinsic value (as of 15 January 2026) is ₹0.96 which is 88.46% lower the current market price of ₹8.32, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹109 Cr. market cap, FY2025-2026 high/low of ₹18.8/7.75, reserves of ₹41 Cr, and liabilities of ₹122 Cr.
What is the Market Cap of Vaishali Pharma Ltd?
The Market Cap of Vaishali Pharma Ltd is 109 Cr..
What is the current Stock Price of Vaishali Pharma Ltd as on 15 January 2026?
The current stock price of Vaishali Pharma Ltd as on 15 January 2026 is ₹8.32.
What is the High / Low of Vaishali Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vaishali Pharma Ltd stocks is ₹18.8/7.75.
What is the Stock P/E of Vaishali Pharma Ltd?
The Stock P/E of Vaishali Pharma Ltd is .
What is the Book Value of Vaishali Pharma Ltd?
The Book Value of Vaishali Pharma Ltd is 5.16.
What is the Dividend Yield of Vaishali Pharma Ltd?
The Dividend Yield of Vaishali Pharma Ltd is 0.00 %.
What is the ROCE of Vaishali Pharma Ltd?
The ROCE of Vaishali Pharma Ltd is 4.93 %.
What is the ROE of Vaishali Pharma Ltd?
The ROE of Vaishali Pharma Ltd is 1.52 %.
What is the Face Value of Vaishali Pharma Ltd?
The Face Value of Vaishali Pharma Ltd is 2.00.